Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect

Executive Summary

Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.

Advertisement

Related Content

Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity
If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market
FDA Rebukes Egalet's Reliance On OxyContin Postmarketing Data
FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says
Opioids With Abuse-Deterrent Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel